6 research outputs found

    A list of OGT substrates identified on nuclear hormone receptor interaction peptide microarray.

    No full text
    <p>A list of OGT substrates identified on nuclear hormone receptor interaction peptide microarray.</p

    Validation of RBL-2_410–422 O-GlcNAcylation.

    No full text
    <p>A, O-GlcNAcylation of RBL-2_410–422 peptide by bacterial lysate containing m-OGT (7 μg/μL) with increasing concentration of UDP-GlcNAc (0–10 mM). B, O-GlcNAcylation of RBL-2_410–422 peptide dependency of increasing total protein concentrations of bacterial lysate containing m-OGT (0, 1.7, 3.5, 7 μg/μL) at 1 mM UDP-GlcNAc. C, O-GlcNAcylation of RBL-2_410–422 peptide by purified m-OGT (0.2 μg/μL) with 1 mM UDP-GlcNAc was inhibited by a known OGT inhibitor (ST045849, 0–200 μM). D, Km value for UDP-GlcNAc was determined with fixed saturating concentration of RBL-2_410–422 peptide, purified m-OGT (0.2 μg/μL) and varying concentration of UDP-GlcNAc (0–2 mM). The Km value derived from the fit to Michaelis-Menten model is 24 μM.</p

    Identification of human OGT substrates from a kinase substrate and nuclear hormone receptor interaction peptide microarray.

    No full text
    <p>The assay was performed using bacterial lysates containing s-OGT (7 μg/μL), m-OGT (7 μg/μL), or nc-OGT (7 μg/μL), respectively, and in all cases in the presence of UDP-GlcNAc (1 mM). A parallel reaction without UDP-GlcNAc was used as a negative control. Representative images from the kinase substrate peptide microarray (A) and nuclear receptor interaction peptide microarray (B) are shown. Reference spot is highlighted in gray and peptide O-GlcNAcylation by all three isoforms of OGT is highlighted in red. O-GlcNAcylation of each peptide by the three isoforms OGT was quantified and corrected for non-specific signal by subtracting the signal generated without UDP-GlcNAc (from signal with UDP-GlcNAc). Representative heat maps are shown for O-GlcNAcylation of kinase substrate peptides (C) and nuclear receptor interaction peptides (D).</p

    S420A is a possible O-GlcNAc site in the RBL-2 protein.

    No full text
    <p>A, peptide mutant used for an Ala scan. For immobilization purposes, peptides were prepared with an extra CG at the N-terminus and Cys 415 was replaced by Ala. B, OGT activity against RBL-2_410–422 peptide mutants was determined using peptide microarray analysis with 0.2 μg/μL purified m-OGT and 1 mM UDP-GlcNAc. C, UDP-Glo assay was used to measure O-GlcNAcylation of RBL-2_410–422 peptide mutants as well. D, kinetic signals from the same microarray experiment of panel B are shown.</p

    The RBL-2_S420A 410–422 peptide inhibited OGT activity.

    No full text
    <p>The inhibitory effect of RBL-2_S420A 410–422 peptide on OGT activity was determined on the nuclear receptor interaction peptide microarray. The reaction was performed by incubating a mixture of purified m-OGT (0.2 μg/μL) and UDP-GlcNAc (0.5 mM) with or without the S420A RBL2 peptide (0.5 mM). The known OGT inhibitor (ST045849) and a no UDP-GlcNAc reaction were used for positive and negative control, respectively. O-GlcNAcylation of NCOA6_1479–1501 peptide (A) and WIPI_1313–318 peptide (B) are shown for the inhibitory effect of RBL-2_S420A 410–422 peptide on OGT activity.</p
    corecore